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Accumulating evidence suggests that activated factor X (FXa), a key coagulation factor, plays an 2 
important role in the development of vascular inflammation through activation of many cell types. 3 
Here, we investigated whether pharmacological blockade of FXa attenuates neointima formation 4 
after wire-mediated vascular injury. Transluminal femoral artery injury was induced in C57BL/6 5 
mice by inserting a straight wire. Rivaroxaban (5 mg/kg/day), a direct FXa inhibitor, was 6 
administered from one week before surgery until killed. At four weeks after surgery, rivaroxaban 7 
significantly attenuated neointima formation in the injured arteries compared with control 8 
(P<0.01). Plasma lipid levels and blood pressure were similar between the rivaroxaban-treated 9 
group and non-treated group. Quantitative RT-PCR analyses demonstrated that rivaroxaban 10 
reduced the expression of inflammatory molecules (e.g., IL-1β and TNF-α) in injured arteries at 11 
seven days after surgery (P<0.05, respectively). In vitro experiments using mouse peritoneal 12 
macrophages demonstrated that FXa increased the expression of inflammatory molecules (e.g., 13 
IL-1β and TNF-α), which was blocked in the presence of rivaroxaban (P<0.05). Also, in vitro 14 
experiments using rat vascular smooth muscle cells (VSMC) demonstrated that FXa promoted 15 
both proliferation and migration of this cell type (P<0.05), which were blocked in the presence of 16 
rivaroxaban. Inhibition of FXa by rivaroxaban attenuates neointima formation after wire-mediated 17 
vascular injury through inhibition of inflammatory activation of macrophages and VSMC. 18 
 19 
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1. Introduction 1 
Angioplasty, especially stent implantation for coronary artery disease, is now established as a 2 
therapeutic strategy of great benefit (Stone, 2008a; b). However, restenosis remains the main 3 
limitation of percutaneous coronary intervention (Hoffmann et al., 1996; Lowe et al., 2002; 4 
Serruys et al., 2006). Excessive neointimal hyperplasia after vascular injury contributes to 5 
restenosis after angioplasty (Hoffmann and Mintz, 2000). Both monocyte/macrophage-dependent 6 
inflammation and vascular smooth muscle cell (VSMC) proliferation play causal roles in this 7 
disease process through multiple cellular and molecular mechanisms (Toutouzas et al., 2004). 8 
Previous studies have demonstrated a link between the blood coagulation system and 9 
inflammatory diseases (Borissoff et al., 2011; Croce and Libby, 2007). A number of previous 10 
studies investigated the role of activated factor X (FXa) in vascular inflammation (Rothmeier and 11 
Ruf, 2012). Recently, we reported that a direct FXa inhibitor, rivaroxaban, attenuates 12 
atherosclerotic plaque progression and destabilization in apolipoprotein E-deficient mice through 13 
inhibition of pro-inflammatory activation of macrophages (Hara et al., 2015). Other studies also 14 
reported inflammatory activation of VSMC and endothelial cells by FXa in vitro (Busch et al., 15 
2005; Kaiser et al., 2000). FXa-induced activation of protease activated receptor (PAR)-1 and 16 
PAR-2 is suggested to be an underlying mechanism. In fact, several studies have shown the 17 
contribution of PAR-1 and PAR-2 (Andrade-Gordon et al., 2001; Chieng-Yane et al., 2010; 18 
Takada et al., 1998; Tennant et al., 2008) to the development of vascular lesions and 19 
inflammation. However, the impact of rivaroxaban on neointima formation after mechanical 20 
vascular injury has not been evaluated. 21 
In this study, we therefore examined the effects of rivaroxaban, the first oral 22 




anticoagulant that directly inhibits FXa (Perzborn et al., 2011), on neointima hyperplasia and 1 
inflammatory features of injured arteries in mice, and also performed in vitro studies using 2 
macrophages and VSMC, key players in neointima formation, to reveal the mechanisms. Our 3 
results suggested that rivaroxaban attenuates inflammatory activation of macrophages and 4 
VSMC, leading to the suppression of neointima hyperplasia after mechanical vascular injury in 5 
mice. 6 
 7 
2. Materials and Methods 8 
2.1. Animals and treatments 9 
C57BL/6J male mice purchased from Japan SLC, Inc. were used in this study. Mice received a 10 
normal chow diet supplemented with or without rivaroxaban (5 mg/kg body weight/day) from 7-11 
weeks-old to kill. Rivaroxaban was supplied by Bayer Pharma AG. Non-treated mice served as 12 
the control. Femoral artery endovascular injury was induced in mice in both the rivaroxaban-13 
treated and non-treated groups at the age of 8 weeks, as described previously (Sata et al., 2000). 14 
Mice were euthanized at 7 days or 4 weeks after surgery, and the femoral arteries were isolated 15 
for further analyses. The mice were housed in a room in which lighting was controlled (12 h on/12 16 
h off), and room temperature was kept at 25 °C. All experimental procedures conformed to the 17 
guidelines for animal experimentation of Tokushima University.  18 
2.2. Blood pressure and laboratory data 19 
Blood pressure measurement was performed using a tail-cuff system (BP-98A, Softron) as 20 
described previously (Salim et al., 2016). Blood was collected from the left ventricle at the time of 21 
sacrifice, and plasma was isolated and stored at -80°C until required. Plasma lipid levels were 22 




measured using commercially available kits (Wako Diagnostics). Rivaroxaban concentration was 1 
determined in lithium-heparin plasma by Shin Nippon Biomedical Laboratories, Ltd. (Japan).  2 
2.3. Analyses of femoral arteries 3 
For morphometric studies, the femoral arteries were harvested at 7 days or 4 weeks after 4 
surgery, and embedded in paraffin after fixation with 10% buffered formalin. Embedded femoral 5 
arteries were cut into 5-μm-thick sections for further analyses. Cross sections were stained with 6 
Elastica van Gieson staining to perform morphometric analysis. Digitalized images were 7 
analyzed with the FLOVEL Filing System (FLOVEL Company, Ltd., Tokyo, Japan). The lumen, 8 
internal elastic lamina, and external elastic lamina were defined. The areas of the intima (tissue 9 
between lumen and internal elastic lamina) and media (tissue between internal elastic lamina and 10 
external elastic lamina) were recorded. Neointima/media area ratio (I/M ratio) was calculated. 11 
Accumulation of smooth muscle cells or macrophages in neointima was examined by 12 
immunohistochemistry. Sections were incubated with alkaline phosphatase-conjugated anti-α-13 
smooth muscle actin (α−SMA) antibody (Sigma) or anti-Mac3 (BD Pharmingen) antibody. 14 
Development was performed by Vector Red substrate (Vector) for α−SMA or the combination of 15 
HRP-conjugated secondary antibody and ImmPACT DAB substrate (Vector Laboratories) for 16 
Mac3. Sections were counterstained with hematoxylin. The percentage of Mac3-pisitive cells in 17 
neointima was calculated. For gene expression analysis, the femoral arteries were harvested at 7 18 
days after surgery and snap-frozen in liquid nitrogen for gene expression analysis. 19 
2.4. Cell culture 20 
Murine resident peritoneal macrophages were cultured in DMEM supplemented with 10% fetal 21 
bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin in a 5% CO2 humidified 22 




atmosphere. To investigate the effects of FXa on macrophage activation, macrophages were 1 
stimulated with 10 nM FXa (Haematologic Technologies, Inc.) for 24 h after 24-h serum 2 
starvation. Additionally, 1 µM or 10 µM rivaroxaban was used to block the effects of FXa. To 3 
assess the effect of PAR-1 or PAR-2, the major receptor of FXa, on macrophage activation, cells 4 
were treated with 10 nM PAR-1 specific agonist peptide (AP-1; Sigma-Aldrich) or 10 nM PAR-2 5 
specific agonist peptide (AP-2; Sigma-Aldrich) for 24 h after 24-h serum starvation. 6 
2.5. Reverse transcription and real-time polymerase chain reaction 7 
Extraction of total RNA from femoral arteries or cells, and reverse transcription were performed 8 
using an illustra RNAspin RNA Isolation Kit (GE Healthcare) and QuantiTect Reverse 9 
Transcription kit (Qiagen), respectively. Quantitative real-time PCR (qPCR) was performed using 10 
an Mx3000P (Agilent Technologies) and Power SYBR Green PCR Master Mix (Applied 11 
Biosystems). The sequences of gene-specific primers are presented in Table 1. Data are 12 
expressed in arbitrary units normalized by β-actin. 13 
2.6. Cell proliferation assay 14 
Rat VSMC were isolated and cultured as described previously (Sreejayan and Yang, 2007). To 15 
evaluate the effects of FXa on migration of rat VSMC, a scratch wound assay was performed as 16 
reported previously. VSMC were seeded in 24-well plates and allowed to attach. After scraping off 17 
the cell monolayer in a straight line, cells were incubated with FXa (10 nM) with or without 18 
rivaroxaban (1 µM) for 24 h. Then, the distance between one side of the scratch and the other 19 
was measured. 20 
A cell proliferation assay was performed using a commercially available kit (CellTiter 96, 21 
Promega) according to the manufacturer's instructions to evaluate the effect of FXa on the growth 22 




of rat VSMC. Rat VSMC were seeded in 96-well plates at an initial density of 1×104 cells/well and 1 
allowed to attach for 24 h. After serum starvation for 24 h, cells were incubated with FXa (10 nM) 2 
with or without rivaroxaban (1 µM) for 24 h. 3 
2.7. Statistical analysis 4 
Numerical values are expressed as mean ± S.E.M. Comparison of parameters between two 5 
groups was performed using unpaired Student's t-test. Differences between multiple groups were 6 
analyzed by one-way analysis of variance, followed by the Scheffe's post hoc analysis. A value of 7 
P <0.05 was considered significant. 8 
 9 
3. Results 10 
3.1. PAR-1 and PAR-2 increased in injured artery 11 
We examined the expression of PARs in the femoral artery in wild-type mice. qPCR analysis 12 
showed that mechanical vascular injury significantly increased PAR-1 and tended to increase 13 
PAR-2 in injured arteries at 7 days after surgery compared with non-injured arteries (Fig. 1). 14 
There were no significant differences in the expression of PAR3 and PAR4 between injured and 15 
non-injured arteries.  16 
3.2. Rivaroxaban did not change metabolic parameters 17 
After 4 weeks of rivaroxaban administration, body weight gain, blood pressure, plasma glucose 18 
level, and plasma lipid levels did not differ between rivaroxaban-treated mice and non-treated 19 
mice (Table 2). After 4 weeks of treatment, plasma level of rivaroxaban was 28.1 ± 3.2 μg/l in the 20 
treated group. 21 
3.3. Rivaroxaban attenuated neointima formation after vascular injury 22 




Histological analysis using femoral arteries harvested at 4 weeks after surgery showed that 1 
rivaroxaban treatment significantly attenuated neointima hyperplasia compared with the non-2 
treatment group (Fig. 2). Rivaroxaban significantly reduced neointima area (30,453 ± 1,982 vs. 3 
19,582 ± 2,981 μm2; P=0.01) and intima/media ratio (4.37 ± 0.49 vs. 2.60 ± 0.51; P=0.03) 4 
compared with control. The most of cell-type in the neointima at 4 weeks after surgery was 5 
smooth muscle cell. There was no difference in cross sectional area of the media between the 6 
groups (9,460 ± 1,723 vs. 10,215 ± 1,734 μm2; P=0.76). Non-injured arteries did no show 7 
neointima in the rivaroxaban group and the control group. These results indicate that rivaroxaban 8 
attenuates neointima formation after vascular injury without alteration of metabolic parameters. 9 
3.4. Rivaroxaban reduced expression of inflammatory molecules in injured artery 10 
Previous studies demonstrated the contribution of pro-inflammatory activation of macrophages to 11 
the development of neointima formation at earlier time point of lesion development (Lavin et al., 12 
2014; Schober and Weber, 2005). Therefore, we investigated the effect of rivaroxaban on 13 
vascular inflammation in injured arteries at 7 days after surgery. The result of 14 
immunohistochemistry demonstrated that rivaroxaban reduced macrophage accumulation in 15 
neointima (P=0.02) (Fig. 3A). qPCR analysis demonstrated that rivaroxaban reduced the 16 
expression of the macrophage marker F4/80 (P=0.006) compared with the control group. 17 
Rivaroxaban treatment also reduced the expression of inflammatory mediators, such as 18 
monocyte chemoattractant protein (MCP)-1 (P=0.009), interleukin (IL)-1β (P=0.01) and tumor 19 
necrosis factor (TNF)-α (P=0.03) (Fig. 3B). Rivaroxaban also decreased mRNA expression of 20 
transforming growth factor (TGF)-β1 (P=0.003), stromal cell-derived factor (SDF)-1 (P=0.0002) 21 
and granulocyte-macrophage colony stimulating factor (GM-CSF) (P=0.04) in the injured artery 22 




(Fig. 3C).  1 
3.5. FXa-PARs signal promoted pro-inflammatory activation of macrophages 2 
To investigate the molecular mechanism by which inhibition of FXa signaling prevented vascular 3 
inflammation and neointima formation without improvement of metabolic parameters, we 4 
performed in vitro experiments using resident peritoneal macrophages obtained from wild-type 5 
mice. The results of qPCR analysis demonstrated that FXa, a major ligand of PAR-1 and PAR-2, 6 
significantly increased mRNA expression of inflammatory molecules (e.g., IL-1β, IL-6 and TNF-α), 7 
which was attenuated in the presence of rivaroxaban in a dose-dependent manner (Fig. 4A). 8 
Furthermore, a specific agonist peptide of PAR-1 or PAR-2 also increased the expression of 9 
inflammatory molecules in this cell type (Fig. 4B).  10 
3.6. Rivaroxaban attenuated vascular smooth muscle cell proliferation and migration 11 
To investigate the mechanism by which rivaroxaban attenuates lesion formation after mechanical 12 
vascular injury, we also investigated the effects of rivaroxaban on migration and proliferation of 13 
VSMC, which is one of the important mechanisms of neointima formation after vascular injury. 14 
The results of scratch-wound assay and MTS assay using rat VSMC demonstrated that FXa 15 
promoted both proliferation and migration of this cell type (Fig. 5A-C). Rivaroxaban attenuated 16 
FXa-induced proliferation and migration of VSMC.  17 
 18 
4. Discussion 19 
In this study, we demonstrated that rivaroxaban, a specific inhibitor of FXa, attenuated neointima 20 
formation after mechanical vascular injury in mice. We also demonstrated that rivaroxaban 21 
inhibited pro-inflammatory activation of macrophages, and proliferation and migration of VSMC, 22 




which are important mechanisms of neointima hyperplasia. Accumulating evidence suggests that 1 
the FXa-PARs signaling contributes to the pathogenesis of inflammatory diseases (Borissoff et 2 
al., 2011; Croce and Libby, 2007), although little is known about the effect of rivaroxaban 3 
treatment on the development of neointima after mechanical vascular injury. 4 
Previous studies reported the contribution of FXa-PARs signaling to the development of 5 
vascular lesions after vascular injury. Expression of PARs in the vasculature has been reported. 6 
In addition, several studies have reported that mechanical vascular injury increased the 7 
expression of PAR-1 and PAR-2 (Cheung et al., 1999; Damiano et al., 1999). The results of our 8 
present study are consistent with those studies. These results suggested that PAR-1 and PAR-2, 9 
and their ligand FXa may play a role in the pathogenesis of neointima formation after vascular 10 
injury. In a carotid ligation model, another commonly used vascular injury model, PAR-2 deletion 11 
significantly reduced neointima formation (Tennant et al., 2008). PAR-1, another FXa receptor, 12 
also participates in neointima formation after vascular injury. Previous studies reported that a 13 
selective blocking antibody or antagonists against PAR-1 reduced neointima formation in 14 
vascular injury models (Andrade-Gordon et al., 2001; Chieng-Yane et al., 2010; Takada et al., 15 
1998). Furthermore, several studies demonstrated that pharmacological blockade of FXa 16 
suppressed neointima formation after vascular injury using animal models (Kaiser et al., 2000; 17 
Ragosta et al., 1994). The results of our present study demonstrating that rivaroxaban, the first 18 
direct oral anticoagulant that inhibits FXa, suppressed neointima hyperplasia correspond to the 19 
results of previous studies. These results implicate causal roles of FXa-PARs signaling in 20 
neointima hyperplasia after vascular injury, and suggested the potency of rivaroxaban, a clinical 21 
approved direct oral FXa inhibitor, for the inhibition of restenosis after angioplasty. 22 




 A large amount of evidence has demonstrated the involvement of various cellular and 1 
molecular pathways in neointima hyperplasia (Toutouzas et al., 2004). Angioplasty improves 2 
blood flow, but meanwhile causes endothelial denudation and impaired endothelial function, 3 
leading to activation of the coagulation system and/or endothelium-leukocyte interaction (Costa 4 
and Simon, 2005). Acceleration of neointima hyperplasia through activation of platelet and 5 
coagulation cascades has been already reported (Chandrasekar and Tanguay, 2000; Vicente et 6 
al., 2007). Therefore, the anti-coagulant effects of rivaroxaban might have an impact on 7 
suppression of neointima hyperplasia. FXa-PARs signaling plays a key role in the coagulation 8 
cascade, whereas accumulating evidence suggests that it also directly contributes to the 9 
pathophysiology of vascular inflammation and neointima hyperplasia. Studies using PAR-2-10 
deficient mice showed reduced endothelium-leukocyte interaction after vascular injury (Tennant 11 
et al., 2008). Stimulation of vascular inflammation by PAR-2 signaling, especially in non-12 
hematopoietic cells, in BERK mice, a model of sickle cell disease, was also reported 13 
(Sparkenbaugh et al., 2014). Pharmacological blockade of FXa also inhibited SMC proliferation in 14 
injured vessels (Kaiser et al., 2000). Furthermore, recent studies including our own revealed that 15 
FXa-PAR2 signaling promotes pro-inflammatory activation of monocyte/macrophages, key 16 
players in vascular inflammation (Hara et al., 2015). In this study, we demonstrated that injured 17 
arteries harvested from rivaroxaban-treated animals showed less macrophage accumulation and 18 
reduced expression of inflammatory molecules such as MCP-1. Rivaroxaban treatment reduced 19 
the expression of growth factors that stimulate proliferation and migration of SMC such as TGF-20 
β1 (Ryan et al., 2003; Tsai et al., 2009) and SDF-1 (Schober et al., 2003; Zernecke et al., 2005). 21 
We further demonstrated that FXa promotes pro-inflammatory activation of macrophages and 22 




proliferation and migration of SMC, which were blocked in the presence of rivaroxaban. The 1 
results of these in vivo and in vitro studies are consistent with those of previous studies and 2 
indicate inhibitory effects of rivaroxaban on the inflammatory activation of these cell types and 3 
neointima formation. 4 
Recent clinical trials using rivaroxaban demonstrated that it might reduce cardiovascular 5 
events in patients with acute coronary syndrome compared with the control (Mega et al., 2009; 6 
Mega et al., 2012; Mega et al., 2013). Furthermore, recently, the result of the Cardiovascular 7 
Outcomes for People Using Anticoagulation Strategies (COMPASS) trial was reported 8 
(Eikelboom et al., 2017). In that study, rivaroxaban (2.5 mg twice daily) plus aspirin group had 9 
better cardiovascular outcomes compared with aspirin alone group. The anti-coagulation effects 10 
of rivaroxaban might play a role in these results, although, considering the results of our present 11 
study and previous studies, the suppression of neointima formation through the attenuation of 12 
vascular inflammation by rivaroxaban might also partially explain this result. Several direct oral 13 
anti-coagulants are now available (Furugohri et al., 2008; Perzborn et al., 2005; Pinto et al., 2007; 14 
Wienen et al., 2007). Further studies are needed to investigate the effects of these drugs on 15 
neointima hyperplasia and their underlying mechanisms. 16 
In conclusion, rivaroxaban suppressed neointima hyperplasia in a mouse mechanical 17 
vascular injury model. Attenuation of vascular inflammation by inhibiting FXa-PARs signals might 18 
have at least partial roles in this result. Our results suggest that the blockade of FXa-PARs 19 
signals by rivaroxaban is a potential therapeutic strategy to attenuate neointima hyperplasia after 20 
mechanical vascular injury, which is a major limitation of angioplasty. 21 
 22 
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Figure legends 1 
Fig. 1. Expression of PARs in injured artery. 2 
Results of qPCR analysis using injured arteries in wild-type mice at 7 days after surgery 3 
demonstrated higher expression of PAR-1 and PAR-2 compared with non-injured arteries. 4 
Expression of PAR-3 and PAR-4 did not differ between injured and non-injured arteries. (n = 4-5). 5 
*P<0.05. All values are mean ± S.E.M. 6 
 7 
Fig. 2. Effects of rivaroxaban on neointima formation. 8 
Elastica van Gieson staining or immunostaining for α-SMA of injured arteries at 4 weeks after 9 
surgery. Rivaroxaban treatment reduced neointima area and intima/media ratio compared with 10 
control group. There was no difference in cross-sectional area of the media between the groups. 11 
The major cell population in the neointima at 4 weeks after surgery was smooth muscle cell. Non-12 
injured arteries did no show neointima in the rivaroxaban group and the control group. Bar: 100 13 
μm. (n = 10-12, per group). Ctrl; control, Riv; rivaroxaban, EVG; Elastica van Gieson, α-SMA; α-14 
smooth muscle actin. Arrow heads indicate the internal elastic lamina. *P<0.05. All values are 15 
mean ± S.E.M. 16 
 17 
Fig. 3. Effects of rivaroxaban on inflammation in injured artery. 18 
(A) The results of immunohistochemistry against Mac3 on injured arteries at 7 days after surgery. 19 
Rivaroxaban reduced the infiltration of macrophages into neointima. (n = 4-5). Bar: 20 μm. (B 20 
and C) The results of qPCR analyses using injured arteries at 7 days after surgery. Rivaroxaban 21 
treatment decreased the expression of F4/80, a macrophage marker. Rivaroxaban also reduced 22 




the expression of inflammatory molecules, such as MCP-1, IL-1β and TNF-α, in the injured 1 
arteries (B). Rivaroxaban also attenuated the expression of several growth factors, such as TGF-2 
β1, SDF-1 and GM-CSF (C). (n = 4-5). Ctrl; control, Riv; rivaroxaban, L; lumen, M; media. 3 
*P<0.05 and **P<0.01. All values are mean ± S.E.M. 4 
 5 
Fig. 4. Effects of FXa on macrophage activation. 6 
(A) The results of qPCR analysis demonstrated that murine resident peritoneal macrophages 7 
treated with FXa showed increased expression of IL-1β, IL-6, and TNF-α compared with the 8 
control. The expression of these inflammatory molecules was attenuated in the presence of 9 
rivaroxaban in a dose-dependent manner. (All values are mean ± S.E.M. of 6 different 10 
experiments). (B) The results of qPCR analysis demonstrated that murine resident peritoneal 11 
macrophages treated with a specific agonist peptide of PAR-1 or a specific agonist peptide of 12 
PAR-2 showed increased expression of inflammatory molecules. (All values are mean ± S.E.M. 13 
of 4 different experiments). NT: no treatment, FXa: activated factor X, Riv: rivaroxaban, AP-1: 14 
specific agonist peptide of PAR-1, AP-2: specific agonist peptide of PAR-2. *P<0.05, **P<0.01, 15 
and ***P<0.0001.  16 
 17 
Fig. 5. Effects of FXa on VSMC migration and proliferation. 18 
(A and B) Representative figures of scratch-wound assay using rat VSMC at 24 h after treatment 19 
(A). FXa promoted the migration of this cell type, which was blocked in the presence of 20 
rivaroxaban (B). (n = 6 per group) (C) MTS proliferation assay using rat VSMC demonstrated that 21 
FXa promoted the proliferation of this cell type after 24 h of treatment. Rivaroxaban attenuated 22 




FXa-induced proliferation. (n = 6 per group) NT: no treatment, FXa: activated factor X, Riv: 1 
rivaroxaban. *P<0.05, **P<0.01, and ***P<0.001. All values are mean ± S.E.M. 2 
  3 




Table 1. Primer sequences. 1 
 Forward  Reverse  
PAR-1 5’-gtcttcccgcgtccctat-3’ 5’-gggttcaccgtagcatctgt-3’ 
PAR-2 5’-ggaccgagaaccttgcac-3’ 5’-gaacccctttcccagtgatt-3’ 
PAR-3 5’-ttctgccagtcactgtttgc-3’ 5’-ggttggctttgctgagttgt-3’ 
PAR-4 5’-tgtagagagtaccaggggaagc-3’ 5’-aggacttcggctccttgagt-3’ 
F4/80 5’-tgcatctagcaatggacagc-3’ 5’-gccttctggatccatttgaa-3’ 
MCP-1 5’-ccactcacctgctgctactcat-3’ 5’-tggtgatcctcttgtagctctcc-3’ 
IL-1β 5’-gcccatcctctgtgactcat-3’ 5’-aggccacaggtattttgtcg-3’ 
TNF-α 5’-accctcacactcagatcatcttc-3’ 5’-tggtggtttgctacgacgt-3’ 
TGF-β1 5’-ggagagccctggataccaac-3’ 5’-cgcacacagcagttcttctc-3’ 
SDF-1 5’-gctctgcatcagtgacggta-3’ 5’-taatttcgggtcaatgcaca-3’ 
GM-CSF 5’-atgcctgtcacgttgaatga-3’ 5’-atatcttcaggcgggtctgc-3’ 
IL-6 5’-acaaccacggccttccctactt-3’ 5’-cacgatttcccagagaacatgtg-3’ 
β-actin 5’-cctgagcgcaagtactctgtgt-3’ 5’-gctgatccacatctgctggaa-3’ 
  2 




Table 2. Effects of rivaroxaban on metabolic parameters. 1 
 Control (n=10) Rivaroxaban (n=12) P value 
Body weight, g 24.8±0.4 25.2±0.4 0.40 
Heart rate /min 706±14 677±13 0.63 
Systolic BP, mmHg 111.8±2.2 108.2±2.0 0.15 
Diastolic BP, mmHg  80.6±2.5 79.0±2.3 0.46 
Plasma glucose, mg/dl 158.0±13.8 145.1±12.6 0.50 
Triglyceride, mg/dl 62.4±6.7 66.2±6.1 0.68 
Total cholesterol, mg/dl 89.3±2.6 89.8±2.4 0.90 
HDL-C, mg/dl 49.7±2.2 48.8±2.0 0.77 
LDL-C, mg/dl 27.1±2.2 27.7±2.0 0.85 
Rivaroxaban, µg/l N.D. 28.1±3.2  - 
BP; blood pressure. HDL-C; high-density lipoprotein cholesterol. LDL-C; low-density lipoprotein 2 
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